Uncategorized

Horizon Therapeutics plc Announces FDA Approval of an Update to the Indication Language for TEPEZZA® (teprotumumab-trbw) to Specify its Use in Thyroid Eye Disease (TED) Patients Regardless of Disease Activity or Duration

Horizon Therapeutics plc Announces FDA Approval of an Update to the Indication Language for TEPEZZA ® (teprotumumab-trbw) to Specify its Use in Thyroid Eye Disease (TED) Patients Regardless of Disease Activity or Duration.

Horizon Therapeutics plc Announces FDA Approval of an Update to the Indication Language for TEPEZZA® (teprotumumab-trbw) to Specify its Use in Thyroid Eye Disease (TED) Patients Regardless of Disease Activity or Duration Read More »

Phase Genomics Collaborates with Element Biosciences to Optimize Cytogenomics for Liquid and Solid Tumor Samples

Phase Genomics, Inc and Element Biosciences , the developer of an innovative DNA sequencing platform disrupting genomics, today released new details of their first collaboration leveraging Phase Genomics’ proprietary OncoTerra™ cytogenomics platform and the Element AVITI System for next generation sequencing (NGS).

Phase Genomics Collaborates with Element Biosciences to Optimize Cytogenomics for Liquid and Solid Tumor Samples Read More »

Caris Life Sciences to Showcase Research Highlighting the Clinical Value of Comprehensive Molecular Profiling at the American Association for Cancer Research Annual Meeting

Caris Life Sciences® announced that the company and partners within the Caris Precision Oncology Alliance™ will collectively present four studies across 14 tumor types at the 2023 American Association for Cancer Research Annual Meeting being held April 14-19, 2023 in Orlando, Florida, at Booth Number 130.

Caris Life Sciences to Showcase Research Highlighting the Clinical Value of Comprehensive Molecular Profiling at the American Association for Cancer Research Annual Meeting Read More »

Scroll to Top